Moderna’s mRNA cancer vaccine works even better than thought.

The approach works by sampling proteins found only on the patient’s specific cancer cells and then prompting the bodies to make them to prime the immune system. “In 2022, they reported that the combo therapy reduced high-risk patients’ risk of recurrence or death by 44% compared to only Keytruda in the two years after treatment. They’ve now announced that people who received both therapies were 49% less likely to experience recurrence or death a median of three years after treatment compared to people in the Keytruda-only group.” learn more and make sure to read the cell-based therapies link above if you’re curious about the bigger picture

Leave a Reply

Your email address will not be published. Required fields are marked *